Breast Cancer Risk Scores: What the Models Measure
SaveA breast cancer risk score is a percentage from a validated model such as Gail or Tyrer-Cuzick, based on your age, family history, and biopsy record. A 5-year risk of 1.66% or a lifetime risk near 20% shifts your screening and prevention options, and a clinician interprets it with you.
Last updated: July 2026History
What is a breast cancer risk score?
A breast cancer risk score turns your personal details into a single percentage that estimates future risk. The most widely used tool, the Gail model — also called the Breast Cancer Risk Assessment Tool — outputs both a 5-year risk and a lifetime risk 1Ref 1American College of Obstetricians and Gynecologists (2017).Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women.Describes the Gail model's 5-year and lifetime risk outputs, the roughly 20% lifetime-risk threshold for adding MRI, and the average lifetime risk near 13%; notes models are validated for population estimates rather than individual prediction.. According to the American College of Obstetricians and Gynecologists, these models are validated for population-level estimates but are far less precise for any one person 1Ref 1American College of Obstetricians and Gynecologists (2017).Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women.Describes the Gail model's 5-year and lifetime risk outputs, the roughly 20% lifetime-risk threshold for adding MRI, and the average lifetime risk near 13%; notes models are validated for population estimates rather than individual prediction..
A score is not a prediction that you will or will not get breast cancer; average lifetime risk sits near 13%, about 1 in 8 women 1Ref 1American College of Obstetricians and Gynecologists (2017).Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women.Describes the Gail model's 5-year and lifetime risk outputs, the roughly 20% lifetime-risk threshold for adding MRI, and the average lifetime risk near 13%; notes models are validated for population estimates rather than individual prediction.. Seeing your number in context helps you compare it against the standard mammogram timing most average-risk women follow, rather than reacting to the percentage alone.
Which model does a clinician use?
Different models exist because they weigh different information. The Gail model emphasizes reproductive history and prior biopsies but captures only first-degree family history, so it can understate risk for someone with a strong family tree 1Ref 1American College of Obstetricians and Gynecologists (2017).Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women.Describes the Gail model's 5-year and lifetime risk outputs, the roughly 20% lifetime-risk threshold for adding MRI, and the average lifetime risk near 13%; notes models are validated for population estimates rather than individual prediction.. The Tyrer-Cuzick (IBIS) model and genetics-oriented tools weigh detailed family history and, in newer versions, breast density 2Ref 2National Cancer Institute (PDQ Cancer Genetics Editorial Board) (2025).Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version.Covers family-history-weighted risk models such as Tyrer-Cuzick, the role of breast density, and how these models identify candidates for genetic evaluation..
According to the National Cancer Institute, family-history-heavy models better identify candidates for genetic evaluation 2Ref 2National Cancer Institute (PDQ Cancer Genetics Editorial Board) (2025).Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version.Covers family-history-weighted risk models such as Tyrer-Cuzick, the role of breast density, and how these models identify candidates for genetic evaluation.. Because age is one of the strongest inputs, a score from your 30s will read differently once it is recalculated after the perimenopausal transition 1Ref 1American College of Obstetricians and Gynecologists (2017).Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women.Describes the Gail model's 5-year and lifetime risk outputs, the roughly 20% lifetime-risk threshold for adding MRI, and the average lifetime risk near 13%; notes models are validated for population estimates rather than individual prediction.. Knowing your relatives' ages at diagnosis makes any model more accurate than a guess about a lump you have noticed.
What does a high score actually change?
A higher score does not mean treatment; it usually means more screening and a conversation about prevention. Women above about 20% lifetime risk are generally offered annual breast MRI alongside mammography 1Ref 1American College of Obstetricians and Gynecologists (2017).Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women.Describes the Gail model's 5-year and lifetime risk outputs, the roughly 20% lifetime-risk threshold for adding MRI, and the average lifetime risk near 13%; notes models are validated for population estimates rather than individual prediction.. A 5-year Gail risk of 1.66% or higher was the eligibility cutoff in the landmark tamoxifen prevention trial, which found the drug lowered breast cancer incidence in higher-risk women 3Ref 3Fisher B, Costantino JP, Wickerham DL, et al. / National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 Study (1998).Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.The NSABP P-1 prevention trial used a Gail 5-year risk of 1.66% or higher as eligibility and showed tamoxifen reduced breast cancer incidence in higher-risk women..
A later head-to-head trial showed raloxifene worked comparably in postmenopausal women, with a different side-effect profile 4Ref 4Vogel VG, Costantino JP, Wickerham DL, et al. / NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 (2006).Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.The STAR P-2 trial found raloxifene comparable to tamoxifen for reducing invasive breast cancer risk in higher-risk postmenopausal women, with a different side-effect profile.. These risk-reducing medications, typically taken for about 5 years in the prevention trials, are options to weigh rather than requirements 3Ref 3Fisher B, Costantino JP, Wickerham DL, et al. / National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 Study (1998).Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.The NSABP P-1 prevention trial used a Gail 5-year risk of 1.66% or higher as eligibility and showed tamoxifen reduced breast cancer incidence in higher-risk women., and reviewing screenings by age helps you put them beside your other routine checks.
When does a score lead to genetic testing?
A very high score, or specific family patterns, can point toward genetic counseling and BRCA testing. According to the National Cancer Institute, features such as breast cancer before age 50, ovarian cancer, or multiple affected relatives raise the chance of an inherited BRCA1 or BRCA2 change 5Ref 5National Cancer Institute (2024).BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet.Describes family patterns (early breast cancer, ovarian cancer, multiple affected relatives) that raise the chance of a BRCA change and the substantially higher lifetime risk in carriers.. Carriers face a much higher lifetime risk — often cited in the range of about 45% to 70% — which reshapes the whole screening plan 5Ref 5National Cancer Institute (2024).BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet.Describes family patterns (early breast cancer, ovarian cancer, multiple affected relatives) that raise the chance of a BRCA change and the substantially higher lifetime risk in carriers..
Genetic counseling helps you decide whether testing is worthwhile and what a positive or negative result would actually mean. Family history also interacts with hormone therapy decisions, since some risk models factor in hormone use and menopausal status.
When a risk score needs a specialist
A risk score is most useful when a clinician interprets it with you. A primary care clinician or gynecologist can run the model, and a genetic counselor can weigh whether BRCA testing fits your family history 1Ref 1American College of Obstetricians and Gynecologists (2017).Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women.Describes the Gail model's 5-year and lifetime risk outputs, the roughly 20% lifetime-risk threshold for adding MRI, and the average lifetime risk near 13%; notes models are validated for population estimates rather than individual prediction.5Ref 5National Cancer Institute (2024).BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet.Describes family patterns (early breast cancer, ovarian cancer, multiple affected relatives) that raise the chance of a BRCA change and the substantially higher lifetime risk in carriers.. Numbers from an online calculator are a starting point, not a verdict, and small differences rarely change what happens next.
A lifetime estimate near or above 20%, or a strong pattern of early cancers in the family, is the usual reason to seek that referral 1Ref 1American College of Obstetricians and Gynecologists (2017).Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women.Describes the Gail model's 5-year and lifetime risk outputs, the roughly 20% lifetime-risk threshold for adding MRI, and the average lifetime risk near 13%; notes models are validated for population estimates rather than individual prediction.5Ref 5National Cancer Institute (2024).BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet.Describes family patterns (early breast cancer, ovarian cancer, multiple affected relatives) that raise the chance of a BRCA change and the substantially higher lifetime risk in carriers.. Gale can help you assemble the family-history details these models depend on, so the appointment starts with accurate inputs.
Common questions
Related
Breast health
Breast MRI: Who Needs One and Who Doesn'tBreast health
Family History: When Breast Screening Starts EarlyBreast health
High-Risk Breast Screening: MRI Plus Mammogram
Say it back
How would you explain this to someone you love?
Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.
When to have a breast change checked
- —A new lump, skin change, or nipple change is a reason to seek clinician review regardless of your calculated risk score.
- —A family history of breast or ovarian cancer you have not discussed is a reason to ask about a formal risk assessment and genetic counseling.
- —A calculated lifetime risk near or above 20% is a reason to ask whether breast MRI should be added to your screening.
- —Bloody or one-sided spontaneous nipple discharge is a reason to arrange evaluation rather than rely on a low score.
This article is general health education, not medical advice. A breast cancer risk score should be calculated and interpreted with a primary care clinician, gynecologist, or genetic counselor who knows your history.
Did this answer your question?
References
- 1.American College of Obstetricians and Gynecologists (2017). Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000002158 ✓Describes the Gail model's 5-year and lifetime risk outputs, the roughly 20% lifetime-risk threshold for adding MRI, and the average lifetime risk near 13%; notes models are validated for population estimates rather than individual prediction.
- 2.National Cancer Institute (PDQ Cancer Genetics Editorial Board) (2025). Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version. National Cancer Institute (NCI), NIH. link ✓Covers family-history-weighted risk models such as Tyrer-Cuzick, the role of breast density, and how these models identify candidates for genetic evaluation.
- 3.Fisher B, Costantino JP, Wickerham DL, et al. / National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 Study (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute. doi:10.1093/jnci/90.18.1371 ✓The NSABP P-1 prevention trial used a Gail 5-year risk of 1.66% or higher as eligibility and showed tamoxifen reduced breast cancer incidence in higher-risk women.
- 4.Vogel VG, Costantino JP, Wickerham DL, et al. / NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 (2006). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. doi:10.1001/jama.295.23.joc60074 ✓The STAR P-2 trial found raloxifene comparable to tamoxifen for reducing invasive breast cancer risk in higher-risk postmenopausal women, with a different side-effect profile.
- 5.National Cancer Institute (2024). BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet. National Cancer Institute (NCI), NIH. link ✓Describes family patterns (early breast cancer, ovarian cancer, multiple affected relatives) that raise the chance of a BRCA change and the substantially higher lifetime risk in carriers.
5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy